Abstract
Vascular endothelial cell growth factor (VEGF)-C is a critical promoter of tumorigenesis, primarily through its roles in lymphangiogenesis and lymph node metastasis. This study investigates the impact of silencing the VEGF-C gene via RNA interference (RNAi) on the proliferation and apoptosis of mouse breast cancer cells. Three small interfering RNA (siRNA) sequences targeting mouse VEGF-C were transfected into 4T1 cells. Results indicated that siV2 most effectively reduced VEGF-C mRNA and protein levels. In vitro, VEGF-C silencing significantly inhibited cell growth and induced apoptosis, correlated with upregulated cleaved caspase-3 expression. In vivo experiments in BALB/c mice demonstrated that intratumoral injection of siV2 reduced tumor weight and volume. These findings suggest that VEGF-C RNAi is a promising targeted therapy for breast cancer, acting directly on tumor cell survival.
Introduction
Breast cancer mortality is frequently linked to lymphatic metastasis, driven by Vascular Endothelial Growth Factor C (VEGF-C). While traditionally viewed as a paracrine factor for lymphatic vessel growth, emerging evidence suggests VEGF-C also functions as an autocrine survival factor for cancer cells. This study utilizes RNA interference (RNAi) to knock down VEGF-C expression in 4T1 mouse breast cancer cells to evaluate its direct effects on tumor growth and programmed cell death.
Methods
The researchers designed three siRNA sequences (siV1, siV2, siV3) targeting mouse VEGF-C. These were transfected into 4T1 cells using a liposomal approach.
- Validation: Gene silencing was confirmed via RT-PCR (mRNA) and Western blot analysis (protein).
- Cellular Assays: Proliferation was measured by MTT assay, while apoptosis was assessed through Hoechst 33258 staining and flow cytometry.
- In Vivo Study: 4T1 cells were injected into BALB/c mice to establish tumors. The most effective siRNA (siV2) was then administered via intratumoral injection. Tumor metrics and apoptotic markers (TUNEL assay) were subsequently analyzed.
Results
Efficiency of VEGF-C Silencing
Western blot analysis confirmed that all three siRNAs reduced VEGF-C protein levels, with siV2 demonstrating the highest efficiency (approximately 90% reduction compared to controls).
Impact on Cell Proliferation and Apoptosis
In vitro assays showed that silencing VEGF-C significantly attenuated 4T1 cell growth at 48 and 72 hours. The apoptotic rate in the siV2-treated group increased to 27.45%, significantly higher than the control groups. This was accompanied by an increase in cleaved caspase-3, a key executioner of apoptosis.
In Vivo Tumor Suppression
In the mouse model, siV2 treatment led to a significant reduction in both tumor volume and weight. The average tumor weight in the treated group was 2.27g, compared to 3.18g in the control group. TUNEL assays confirmed increased apoptosis within the tumor tissues of treated mice.
Discussion
This study confirms that VEGF-C serves as a direct survival factor for 4T1 breast cancer cells through an autocrine signaling loop. By silencing this gene, researchers triggered the apoptotic pathway, specifically through the activation of caspase-3. The sequence-specific efficacy of siV2 highlights the critical nature of siRNA design in therapeutic applications.
While intratumoral delivery proved effective in this model, clinical translation will require advanced systemic delivery systems, such as nanoparticles, to target metastatic sites. Future research should also map the precise intracellular signaling pathways (e.g., AKT or MAPK) that link VEGF-C receptors to cell survival in this context.
Conclusion
RNAi-mediated silencing of VEGF-C effectively inhibits breast cancer growth and promotes apoptosis both in vitro and in vivo. These results support the development of VEGF-C-targeted RNAi as a potential therapeutic strategy for managing aggressive breast cancers.
Summary updated